Inis Biotech LLC
7 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
4
Ending by 2030
Nov 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due May 17 to 26, 2027 · next May 17
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 9 of 9
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,206,440 | Implantable ocular microapparatus to ameliorate glaucoma or an ocular overpressure causing disease In force · From the USPTO record | In force | From the USPTO record | |
| US 8,501,168 | Cell Lines, Compositions Comprising Them for the Treatment of Melanomas, Procedures to Prepare the Compositions, and Treatment Methods In force · High confidence | In force | High confidence | |
| US 8,431,554 | Compound Showing Anti-Inflammatory Activity and Antiviral Activity, Pharmaceutical Compositions Comprising the Same, a Process for Obtaining the Same and Use of the Same in the Treatment of Epidemic Keratoconjunctivites and Herpetic Stromal Keratis In force · High confidence | In force | High confidence | |
| US 9,187,518 | Antiangiogenic Brassinosteroid Compounds In force · High confidence | In force | High confidence | |
| US 9,511,137 | Adjuvant for vaccines, vaccines that comprise said adjuvant and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,020,478 | Methods for modulating angiogenesis of cancers refractory to anti-VEGF treatment In force · From the USPTO record | In force | From the USPTO record | |
| US 10,857,522 | A Catalytic Process for the Production of Propylene Glycol from Glycerol, a Copper and Cerium Catalyst, and a Process to Produce Such Catalyst In force · High confidence | In force | High confidence | |
| US 10,000,548 | GAL-1 variants having immuno-modulating properties and methods of using the same In force · From the USPTO record | In force | From the USPTO record | |
| US 10,490,866 | METHOD FOR ACID DISSOLUTION OF LiCoO2 CONTAINED IN SPENT LITHIUM-ION BATTERIES In force · High confidence | In force | High confidence |
Also on record, not counted in the 9: 7 patents in force now held by others · 7 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
10 abandoned · 5 no status recorded